The difference between normal and tumor cell responses to Entolimod is likely due to the fact that most tumor cells commonly acquire impairment of pathways controlling cell cycle and DNA repair (e.g., p53), frequently resulting in constitutively active NF-B and STAT3 [38, 44, 45] thus making TLR5 stimulation ineffective. Here, TP53 is linked to neoplasm.